No Data
No Data
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) Adds CN¥373m in Market Cap and Insiders Have a 37% Stake in That Gain
Fangsheng Pharmaceutical 2024 Semi-Annual Report
Summary of Fangsheng Pharmaceutical\'s 2024 Semi-Annual Report
Hunan Fangsheng Pharmaceutical (603998.SH): Net income in the first half of the year was 0.137 billion yuan, a year-on-year increase of 28.23%.
Hunan Fangsheng Pharmaceutical (603998.SH) announced its semi-annual report on August 28. During the reporting period, the company achieved revenue of 0.91 billion yuan, an increase of 6.44% year-on-year. The net income attributable to shareholders of the listed company was 0.137 billion yuan, a year-on-year increase of 28.23%. Among them, the pharmaceutical manufacturing business achieved operating income of 837.1133 million yuan, a year-on-year increase of 9.12%. A cash dividend of 0.50 yuan per 10 shares was distributed to all shareholders registered on the equity registration day.
No Data
No Data